• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mural Oncology plc - Ordinary Shares (NQ:MURA)

2.040 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mural Oncology plc - Ordinary Shares

< Previous 1 2 Next >
News headline image
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
December 05, 2025
From Mural Oncology plc
Via GlobeNewswire
News headline image
Mural Oncology Announces Sanction of the Scheme by the High Court
December 03, 2025
From Mural Oncology plc
Via GlobeNewswire
News headline image
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
November 26, 2025
From Mural Oncology plc
Via GlobeNewswire
News headline image
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
October 24, 2025
From Mural Oncology plc
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PHLT, ARIS, MURA on Behalf of Shareholders
September 27, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Mural Oncology Announces Commencement of Mailing of Definitive Proxy Statement and Details of Scheme Meeting and Extraordinary General Meeting
September 23, 2025
From Mural Oncology plc
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARIS, MTSR, GTLS, MURA on Behalf of Shareholders
September 23, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, GES, MURA, TZUP on Behalf of Shareholders
September 11, 2025
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders
August 20, 2025
From Halper Sadeh LLC
Via Business Wire
News headline image
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update
August 04, 2025
From Mural Oncology plc
Via GlobeNewswire
News headline image
Mural Oncology Announces Plans to Explore Strategic Alternatives
April 15, 2025
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
March 25, 2025
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones
March 11, 2025
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference
February 18, 2025
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
January 09, 2025
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer
November 20, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Announces Third Quarter 2024 Financial Results and Provides Update on Pipeline Progress
November 13, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Participate in Two Upcoming Investor Conferences
November 11, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 07, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 04, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 07, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
September 26, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Strengthens Board of Directors with the Appointment of Sachiyo Minegishi
September 23, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
September 10, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology to Present at Two Upcoming Investor Conferences
August 27, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Announces Second Quarter 2024 Financial Results and Provides Update on Pipeline Progress
August 13, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
News headline image
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From Mural Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap